Supplementary Figure 6: AERSMine workflow to identify potential drug candidates that minimize lithium toxicities. | Nature Biotechnology

Supplementary Figure 6: AERSMine workflow to identify potential drug candidates that minimize lithium toxicities.

From: Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data

Supplementary Figure 6

Example workflow showing AERSMine-facilitated approach to identify drug candidates based on differential AEs that could be significant in managing highly reported lithium toxicities, and indicates key under-represented groups (aggregated safety signals IC < 0 and ranked by high incidence/low risk) for cardiovascular system drugs.

Back to article page